Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

immatics biotechnologies GmbH (IMTXW)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1400+0.0600 (+1.47%)
At close: 3:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.0800
Open4.2200
Bid3.8100 x 1300
Ask4.4200 x 900
Day's Range4.0500 - 4.2000
52 Week Range4.0500 - 4.2000
Volume8,630
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for IMTXW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

      ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indicationsTCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof-of-concept for second TCER® molecule IMA402Cash and cash equivalents as well as Other financial assets of $229.1 million1 (€192.8 million) as of June 30, 2021, funding company operations into 2023 Tuebingen, Ger

    • PR Newswire

      BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

      BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things.

    Advertisement
    Advertisement